Nanomedical Diagnostics Changes Name to Cardea

Nanomedical Diagnostics, a Serra Capital II portfolio company, has announced that it has changed its name to Cardea, to encompass internet biology of things.

Michael Heltzen, the new Co-CEO of Cardea says, “The name Cardea - the Roman goddess of hinges and therefore gates - underlines the pivotal and unique aspect of our proprietary graphene biosensor platform. We allow the biological molecules of interest to be the critical part of the electrical system that makes up our biosensors. This way we connect biology to the digital networks in a way the world has never seen before. This direct integration of biology and computing power gives us a live signal from the complex actions and interactions of the biology we normally think of as disease, health, drugs, food and more.”

Cardea is the world’s leading manufacturer and developer of breakthrough digital graphene biosensors that among other things are being used to power the Internet of Biology. Cardea’s mission is to help transform the life science and healthcare industries with innovative new capabilities that enable Cardea partners to offer the world next-generation pharmaceutical development and monitoring, rapid onsite diagnostics, and cutting-edge life science applications.

Source: https://www.prweb.com/releases/nanomedical_diagnostics_announces_company_name_change_to_cardea_to_encompass_internet_of_biology_initiatives/prweb16034251.htm